BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a BioSante presentation and corporate discussion are available at http://www.rodm.tv/video1269553400.
“This fireside chat is among the most far-reaching discussions we've ever had about our products and we are pleased to make it accessible. I would encourage all those interested in learning more about BioSante to visit the link, http://www.rodm.tv/video1269553400”
Stephen M. Simes, president and CEO of BioSante presented an in-depth view of the Company's strategy, development pipeline and clinical milestones, during an interview by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC (NASDAQ: RODM). The topics discussed included an overview of BioSante and specifically a thorough discussion of LibiGel® (testosterone gel), in development for the treatment of female sexual dysfunction, as well as BioSante's portfolio of GVAX cancer vaccines.
"This fireside chat is among the most far-reaching discussions we've ever had about our products and we are pleased to make it accessible. I would encourage all those interested in learning more about BioSante to visit the link, http://www.rodm.tv/video1269553400," said Simes.
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer